Sino-US biotech company Laekna, Inc. (HKG: 2105) announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its investigational drug LAE120 in advanced solid tumors. The drug, a selective USP1 allosteric inhibitor, has a unique chemical structure that differentiates it from other USP1 inhibitors by its ability to induce conformational changes in the USP1 protein.
Preclinical Results
Preclinical studies have shown that LAE120 has demonstrated good monotherapy efficacy in various tumor models. Additionally, its combination with PARP inhibitors has shown significant synergistic effects. Long-term toxicity studies have indicated that LAE120 has a favorable safety profile. Laekna is currently seeking external partnerships to support the clinical development of the drug.-Fineline Info & Tech
